Odio, Alberto

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,829

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

McClung, M. R., O'Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Kiel, D. P., Cavallari, I., Bonaca, M. P., et al. (2019) · The Lancet Diabetes & Endocrinology

Bone health and osteoporosis researchMenopause: Health Impacts and Treatments

Cited by 169

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial

Sims, M. D., Khanna, S., Feuerstadt, P., Louie, T. J., Kelly, C. R., Huang, E. S., Hohmann, E. L., Wang, E. E. L., Oneto, C., Cohen, S. H., et al. (2023) · JAMA Network Open

Clostridium difficile and Clostridium perfringens researchGut microbiota and health

Cited by 83